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Abstract
Several genes that influence susceptibility to Alzheimer’s disease (AD) have been known for over
two decades. Recent advances have elucidated novel candidate genes and the pathogenetic
mechanisms underlying neurodegeneration in AD. Here, we summarize what we have learned from
studies of the known AD genes with regard to the causes of AD and emerging therapies. We also
review key recent discoveries that have enhanced our understanding of the etiology and
pathogenesis of this devastating disease, based on new investigations into the genes and molecular
mechanisms underlying AD.
Introduction and context
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder and the leading cause of dementia in the
elderly. As the incidence and prevalence of AD rise
steadily with increasing longevity, AD threatens to
become a catastrophic burden on health care, particu-
larly in developed countries [1]. AD patients typically
present with symptoms of global cognitive decline and
loss of memory. Pathologically, the disease is character-
ized by excessive deposition of amyloid deposits (senile
plaques), neurofibrillary tangles, synapse and neuronal
loss, and inflammation in the brain. Among the major
risk factors for AD, the strongest is increasing age
followed by family history [2], gender (females at greater
risk than males), and stroke/head trauma.
Genetics of AD
To date, more than 200 rare and fully penetrant
autosomal-dominant mutations in three genes, the
amyloid precursor protein (APP) and presenilin genes
(PSEN1 and PSEN2), have been shown to cause the
early-onset (<60 years) familial form of AD (EO-FAD),
which accounts for <10% of AD cases [3]. On the other
hand, a common variant, e4, in the gene encoding
apolipoprotein E (APOE) is the only confirmed genetic
risk factor for the late-onset form of AD (LOAD) (>90%
of AD cases). Overall, these four genes together account
for <50% of the genetic variance in AD, and the quest to
identify the remaining genes has been challenging due to
the complex and heterogeneous nature of the disease [4].
Several genes besides APOE have yielded significant
evidence (based on meta-analyses) for association with
LOAD, but with only modest effects [2].
Molecular pathology of AD
Arguably, the genetic discoveries mentioned above have
driven our current understanding of the underlying
molecular basis of AD more than any other findings. The
proteolyticprocessingofAPPandproductionofthemajor
component of b-amyloid, Ab peptide, by two proteases
known as b-a n dg-secretase are key events in the
pathogenesis of disease. The Ab peptide has two major
forms, Ab40, which makes up approximately 90% of Ab in
the brain, and Ab42, which comprises approximately 10%.
In addition, the hyperphosphorylation and aggregation of
the microtubule-associated tau protein drive neurofibril-
lary tangle formation within neurons. Most of the
mutations in the EO-FAD genes increase the ratio of
Ab42/Ab40. The longer form of the peptide, Ab42,i s
consideredtobethemoreneurotoxicspeciesasitenhances
theaggregationofAbintoneurotoxicoligomersandsenile
plaques. Recent studies indicate that Ab42 oligomers and
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neurotransmission,neuronalcelldeath,andinflammation
in the hippocampus and cerebral cortex, thereby causing
loss of memory and global cognition dysfunction.
Therapeutics in AD
Currently available drugs for AD, such as cholinesterase
inhibitors (for example, Aricept®) and the glutamate
antagonist Namenda®, treat mainly the symptoms, with
no known effects on disease progress. Another drug,
dimebolin, which is currently in clinical trials, is a retired
antihistamine that is purported to be neuroprotective
based on stabilizing mitochondria. Given that all four of
the established AD genes lead to enhanced accumulation
of Ab42 in the brain (EO-FAD genes via increased
production of the peptide and APOE via decreased
clearance), most of the current AD therapies in develop-
ment are aimed at either curbing Ab42 production/
aggregation or potentiating its degradation/clearance.
This is being attempted with inhibitors and modulators
of the b- and g-secretases, compounds that attenuate Ab
aggregation (for example, by preventing interaction of
the peptide with copper and zinc), and anti-Ab immuno-
therapy aimed at stimulating the degradation of the
peptide [5].
Major recent advances
Genetics
Given the strong genetic predisposition of AD, there have
been a huge number of studies testing for genetic
association with AD, including over 1,500 polymorph-
isms in over 500 candidate genes. As with most complex
genetic disorders, the AD genetics field is rife with
replications and refutations for hundreds of candidate
genes. Recently, an online database known as ‘AlzGene’
has revolutionized our ability to follow and interpret
these findings. AlzGene [6] is a publicly available
database that provides up-to-date results of all genetic
association reports since 1978 [2]. More importantly, it
provides systematic meta-analyses for all polymorph-
isms (>200) tested in at least four independent study
samples. After APOE, the gene with the strongest genetic
effect on AlzGene was CHRNB2, which encodes the beta-
2 subunit of the nicotinic cholinergic receptor. This is
particularly interesting given that several drugs currently
in clinical trials for AD target the nicotinic receptor. The
advent of high-throughput genotyping arrays has also
enabled ‘unbiased’ genome-wide screening to identify
novel AD genes. To date, six novel LOAD genes have
been reported with genome-wide significance [7-10].
One of these, ATXN1 (ataxin 1), is the gene responsible
for another neurodegenerative disorder, spinal cerebellar
ataxia 1, and another is CD33, a lectin involved in the
innate immune system [10].
Beta-amyloid toxicity
It is widely accepted that excessive b-amyloid deposition
in the brain is a key factor in the pathophysiology of AD
[4]. Valuable clues concerning the mechanism by which
Ab aggregates lead to cognitive dysfunction have
emerged over the last several years. The original amyloid
cascade hypothesis maintained that all AD neuropathol-
ogy, including neuronal cell loss, generation of neurofi-
brillary tangles, and inflammation, occur downstream of
senile plaque formation. However, the amyloid cascade
hypothesis fails to explain the weak correlation between
amyloid deposition and the clinical degree of dementia
in AD [11]. Moreover, the decline in cognition correlates
best with synaptic loss and not plaque counts, implying
that synaptic perturbations cause AD and precede
amyloid plaque deposition [12,13].
A spate of recent studies has initiated a paradigm shift
regarding the molecular mechanism by which Ab
deposition leads to cognitive dysfunction. Over the
past several years, it has become increasingly apparent
that Ab oligomers (for example, dimers) exert detri-
mental effects on synaptic function. More specifically,
soluble Ab oligomers have been shown to specifically
impair long-term potentiation (LTP) and promote
synaptotoxicity. This has led to the synaptic Ab hypo-
thesis [14], which maintains that free and soluble Ab
oligomers, either produced within the synapse or
entering from outside, impair LTP. Furthermore, several
reports indicate that Ab oligomers trigger the internaliza-
tion of post-synaptic AMPA (a-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid)- and NMDA
(N-methyl-D-aspartic acid)-type glutamate receptors
[15,16], leading to loss of spines and inhibition of LTP
(Figure 1a,b) [14,17-20]. More recently, high-affinity
binding between Ab and the cellular prion protein PrP
c
has been reported, suggesting that PrP
c could be an
important mediator in Ab oligomer-induced synaptic
dysfunction [21]. Understanding the interaction between
Ab and other cellular factors could provide new
therapeutic potential in restoring the synaptic plasticity
and possibly reversing AD symptoms.
Future directions
Recent advances have enabled the identification of novel
AD genes as well as new insights into the causes of
memory and cognitive dysfunction in AD. Genome-wide
association studies are gradually elucidating the genetic
basis of AD, similar to the case for schizophrenia and
autism [22,23], by revealing gene defects and affected
biological pathways. Meanwhile, advances in under-
standing how Ab impairs cognition at the synaptic level
couldprovidenewtherapeuticmodalitiesfortreatingand
preventing AD based on restoring the synaptic plasticity.
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Soluble Ab oligomers promote receptor endocytosis, reducing the density of the receptors at the synapses. Ab is secreted into the synaptic cleft via sequential
cleavage of presynaptic amyloid precursor protein (APP) (internally or at the cell surface) by b-secretase and g-secretase or gains entry from outside the
synapse. The accumulation of Ab oligomers in the synaptic cleft leads to reduced NMDA and AMPA receptor density in synapses, leading to attenuated
long-term potentiation (LTP) and neurotransmission. While Ab oligomers may play a normal role in controlling LTP, accelerated synaptic accumulation of Ab
oligomers (for example, due to familial Alzheimer’s disease [AD] gene mutations) may lead to a toxic gain of function and cognitive decline. Ab42,
amyloid-b-protein 42-mer; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-methyl-D-aspartic acid.
Figure 1b. Synaptic Ab hypothesis
Increased accumulation of synaptic Ab oligomers promotes endocytosis of NMDA and AMPA receptors, leading to a reduction in dendritic spines and
reduced long-term potentiation (LTP). Acceleration of this process could lead to a toxic gain of function in the form of an imbalance in the LTP/long-term
depression (LTD) ratio. This, in turn, causes synaptic dysfunction, spine loss, and (potentially) synaptic loss, leading to cognitive decline and AD.
AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-methyl-D-aspartic acid.
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